Evidence map›Paper›PMID 40208315›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Al

Xiaoyi Guo, Xu Liang, Ben Li, Yan Mao, Nina Zhou, Jiayue Liu, Guangjie Yang, Zhenguang Wang, Guohong Song, Zhi Yang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dual-receptor PET imaging of ovarian cancer using aAmerican journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoyi Guo *Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Xu Liang *Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Ben Li *Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
Yan MaoBreast Disease Center, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
Nina ZhouKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Jiayue LiuKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Guangjie YangDepartment of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China.
Zhenguang WangDepartment of Nuclear Medicine, The Affiliated Hospital of Qingdao University, No.59, Haier Road, Qingdao, Shandong, 266061, China. wangzhenguang@qdu.edu.cn.
Guohong SongDepartment of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. songguohong918@hotmail.com.
Zhi YangKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China. pekyz@163.com.ORCID 0000-0003-2084-5193

Funding

and Science Foundation of Peking University Cancer Hospital KC2305Isotope and Pharmaceutical Innovation Fund of National Engineering Research Center of Isotope & Pharmaceutical B00167National Natural Science Foundation of China 82171980Nuclear energy development research project 2023the Capital's Funds for Health Improvement and Research 2022-2Z-2154the Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute 2021-1
6 · The paper itself

Abstract

purposeTo assess the diagnostic performance and the whole-body heterogeneity of HER2 expression on Al

methodsIn this prospective study conducted from November 2021 to March 2024, participants with HER2-low breast cancer underwent both Al

resultsFifty-two participants with HER2-low breast cancer (mean age, 53.0 ± 11.0; 52 females) underwent Al

conclusionThe visualization of HER2-low breast cancer with Al

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Heterocyclic CompoundsHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed TomographyAdultAgedFemaleFluorine RadioisotopesHumansMiddle AgedProspective Studies1,4,7-triazacyclononane-N,N',N''-triacetic acidERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorine RadioisotopesFluorodeoxyglucose F18Heterocyclic CompoundsHeterocyclic Compounds, 1-Ring18F-FDGAl18F-NOTA-HER2-BCHBreast cancerHER2-lowPET/CT

Identifiers

PMID40208315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.